Table 1.

Demographic and clinical characteristics at baseline of refractory chronic migraine patients treated with Erenumab

	Total number of patients
Sex, M/F	27/135
Age (y), mean ± SD	46 ± 14.3
CM duration (y), mean ± SD	13 ± 11.9
Aura, N (%)	53 (33%)
Medication overuse, N (%)	87 (54%)
	Mean ± St. Error
Migraine days	19.7 ± 0.7
Headache days	23.4 ± 0.6
Headache free days	3.7 ± 0.4
Abortive treatment intake days	11.5 ± 0.7
HIT-6 score	67.6 ± 0.4
Number of preventive treatments failed	8.4 ± 3.6
BoNT/A non-responders	148 (91.4%)

BoNTA: onabotulinum toxinA, CM, chronic migraine; F, female; HIT-6, headache impact test-6; M, male; N, number; Y, years